Skip to content

Lung adenocarcinoma — Epidemiology and risk factors

TL;DR — Adenocarcinoma is now the dominant lung-cancer histology in many populations, but its epidemiology is not one disease curve: tobacco remains the principal preventable cause, while never-smoker adenocarcinoma has a different distribution of sex, ancestry, exposures, and oncogenic drivers (Barta 2019, PMID 30741509; Rivera 2016, PMID 26667338). Worldwide subtype estimates for 2022 show large geographic variation and a continuing rise of adenocarcinoma in several populations even as smoking-linked squamous and small-cell rates fall (Luo 2025, PMID 39914442). Second-hand smoke raises lung-cancer risk by about one quarter in lifelong never-smokers, and outdoor particulate matter raises risk per increment of exposure; recent experimental work suggests that PM2.5 can promote expansion of pre-existing EGFR-mutant epithelial clones rather than acting only as a classical mutagen (Hackshaw 1997, PMID 9365295; Hamra 2014, PMID 24911630; Hill 2023, PMID 37020004). The central unresolved prevention problem is that current smoking-based screening rules miss most never-smokers, while risk-enriched CT screening in Taiwan detected many early cancers but did not establish a mortality benefit (Chang 2024, PMID 38042167).

The population burden

Lung cancer was the most commonly diagnosed cancer and leading cause of cancer death in the 2022 GLOBOCAN estimates; those totals combine biologically distinct histologies and should not be treated as adenocarcinoma-specific rates (Bray 2024, PMID 38572751). A 2025 reconstruction using GLOBOCAN 2022 and registry data estimated histology-specific incidence across countries and confirmed that adenocarcinoma has become the leading subtype in most assessed settings, with strong geographic and sex variation (Luo 2025, PMID 39914442).

The shift toward adenocarcinoma is visible within longitudinal registries. In Japan, 62,870 cases from 1993–2015 showed rising adenocarcinoma and localized-stage incidence in both sexes, while squamous and small-cell incidence declined in men and levelled in women; localized adenocarcinoma increased 4.5% per year in men and 5.7% per year in women (Nguyen 2022, PMID 35138642). A North Indian referral series likewise documented adenocarcinoma becoming the most frequent histology, but its retrospective, single-centre design cannot establish population incidence (Mohan 2016, PMID 27146752).

Epidemiologic quantity Estimate or direction Population and method Interpretation
Global lung-cancer burden Leading cancer diagnosis and cancer-death cause in 2022 GLOBOCAN modelling across 185 countries Not histology-specific (Bray 2024, PMID 38572751)
Histology distribution Adenocarcinoma dominant in most assessed countries, with wide geographic variation GLOBOCAN/CI5/AFCRN reconstruction Modelled subtype estimates, not a single global registry (Luo 2025, PMID 39914442)
Japan, localized adenocarcinoma AAPC +4.5% men; +5.7% women 62,870 registry cases, 1993–2015, multiple imputation Detection and diagnostic practice contribute alongside biology (Nguyen 2022, PMID 35138642)
Metastatic lung-cancer 1-y survival 18.4% → 29.4%, 1990–2014 California Cancer Registry, 186,156 cases All histologies; improvement differed by age, sex, race/ethnicity, and histology (Li 2021, PMID 33414054)
US NSCLC mortality −6.3%/y in men, 2013–2016, while incidence fell −3.1%/y SEER incidence-linked mortality Excess mortality decline temporally aligned with treatment diffusion (Howlader 2020, PMID 32786189)

Population curves mix prevention, screening, diagnosis, and treatment. SEER incidence-linked mortality showed that NSCLC mortality fell faster than incidence after targeted treatments entered practice, whereas the same pattern was not seen for small-cell disease (Howlader 2020, PMID 32786189). A subsequent national modelling study attributed most lung-cancer deaths averted from 1975–2020 to tobacco control, with screening and treatment adding later gains; this is a model-based decomposition, not randomized attribution (Goddard 2025, PMID 39636625).

Tobacco exposure: dominant but heterogeneous

Active smoking is the major population cause of lung cancer, but the association varies by histology and exposure measurement (Barta 2019, PMID 30741509). In a prospective female cohort using urinary nicotine metabolites, biochemically confirmed active smokers had 7.8 times the lung-cancer risk of non-smokers; the smoking-related relative risk was lower for adenocarcinoma than for other lung carcinomas, not absent (Ellard 1995, PMID 7669596).

Second-hand smoke produces a smaller but measurable risk. A synthesis of 37 studies and 4,626 never-smoker cases estimated 24% excess lung-cancer risk for living with a smoker (95% CI 13%–36%); adjustment for measured biases yielded 26% (7%–47%) (Hackshaw 1997, PMID 9365295). A later 51-study meta-analysis estimated RR 1.25 (95% CI 1.15–1.37) for spousal exposure and RR 1.17 (1.04–1.32) for workplace exposure, with a lower summary RR for adenocarcinoma than other histologies (Boffetta 2002, PMID 12058801).

Prospective Japanese data sharpen the histology-specific signal. Among 28,414 lifelong never-smoking women followed for 13 years, 109 lung cancers arose and 82 were adenocarcinomas; spousal smoking showed an exposure-dependent association with lung cancer, particularly adenocarcinoma (Kurahashi 2008, PMID 17935128).

Tobacco domain Quantitative evidence Main limitation
Active smoking RR 7.8 for biochemically confirmed smokers vs non-smokers in one female cohort (Ellard 1995, PMID 7669596) One urine measurement; historical cohort
Spousal second-hand smoke RR 1.24 (95% CI 1.13–1.36) across 37 studies (Hackshaw 1997, PMID 9365295) Exposure misclassification and residual confounding
Spousal second-hand smoke, broader synthesis RR 1.25 (1.15–1.37), 51 studies and 7,369 cases (Boffetta 2002, PMID 12058801) Histology-specific estimates less precise
Workplace second-hand smoke RR 1.17 (1.04–1.32) (Boffetta 2002, PMID 12058801) Heterogeneous workplace exposure definitions
Japanese never-smoking women 109 cancers/28,414 women over 13 y; 82 adenocarcinomas (Kurahashi 2008, PMID 17935128) Modest event count

Declining smoking prevalence does not mechanically imply declining adenocarcinoma incidence. Cigarette design, inhalation pattern, latency, aging, diagnostic imaging, and rising recognition of never-smoker disease all alter observed subtype curves; registry trends cannot isolate these contributions (Barta 2019, PMID 30741509; Luo 2025, PMID 39914442).

Never-smoker adenocarcinoma

Lung cancer in never-smokers accounts for roughly one quarter of lung cancers worldwide and is predominantly adenocarcinoma; if counted separately, its US mortality burden would rank among major cancers (Rivera 2016, PMID 26667338). Never-smoker disease is enriched in women and Asian populations and more often contains targetable drivers, but these are population associations rather than diagnostic rules (Pallis 2013, PMID 23921082; Shi 2014, PMID 24419411).

PIONEER prospectively tested 1,450 evaluable advanced Asian adenocarcinomas and found EGFR mutations in 51.4%; frequency varied by country, sex, ethnicity, and smoking status (Shi 2014, PMID 24419411). The 2025 Sherlock-Lung study sequenced treatment-naive cancers from 871 never-smokers across 28 locations: KRAS mutations were 3.8-fold more common in North American/European than East Asian never-smoker adenocarcinomas, whereas EGFR and TP53 mutations were more prevalent in East Asia (Díaz-Gay 2025, PMID 40604281). These data argue against treating “never-smoker lung cancer” as one molecular entity.

Feature Never-smoker pattern Evidence boundary
Histology Adenocarcinoma predominates (Rivera 2016, PMID 26667338) Review-level synthesis
EGFR in advanced Asian adenocarcinoma 51.4% of 1,450 evaluable tumors (Shi 2014, PMID 24419411) Advanced-stage, Asian cohort; not a global prevalence
Geographic molecular variation KRAS 3.8× more frequent in North American/European than East Asian never-smoker adenocarcinoma (Díaz-Gay 2025, PMID 40604281) Sequenced research cohort, not incidence sampling
Survival Never-smokers differ clinically and prognostically from smokers (Clément-Duchêne 2016, PMID 26730864) Treatment-era and driver confounding remain
Screening evidence TALENT enrolled risk-enriched never/light smokers and found a high early-stage detection yield (Chang 2024, PMID 38042167) Single-arm cohort; mortality benefit and overdiagnosis unresolved

The Cancer Care Outcomes Research and Surveillance cohort prospectively identified 274 never-smokers among 3,410 US patients and found demographic, treatment, and survival differences from smokers; those outcome differences cannot be assigned to smoking status alone because stage, sex, comorbidity, and actionable mutations co-vary (Clément-Duchêne 2016, PMID 26730864). See molecular landscape for genotype distributions and screening and early detection for the eligibility problem.

Air pollution and environmental promotion

A meta-analysis of 18 studies estimated lung-cancer risk per 10-µg/m³ increment in particulate exposure and found positive associations for both PM2.5 and PM10, with an especially clear signal for adenocarcinoma (Hamra 2014, PMID 24911630). The observational association is now linked to an experimental mechanism: across four within-country cohorts totalling 32,957 EGFR-driven cases, PM2.5 exposure correlated with incidence; mouse and organoid experiments implicated IL-1β-dependent inflammation and expansion of pre-existing EGFR-mutant cells (Hill 2023, PMID 37020004).

This promoter model matters because normal lung epithelium accumulates oncogenic mutations with age. It does not imply that PM2.5 is harmless to DNA, nor that all pollution-associated tumors are EGFR-driven; it provides one experimentally supported route from exposure to clonal expansion (Hill 2023, PMID 37020004). Sherlock-Lung separately found geographically patterned mutational signatures, including exposure-associated signals, showing that promotion and mutagenesis may coexist (Díaz-Gay 2025, PMID 40604281).

Other susceptibility domains

Domain Best quantified evidence in this build Interpretation
COPD/emphysema Prospective-cohort meta-analysis: COPD SRR 2.06 (95% CI 1.50–2.85); emphysema 2.33 (1.56–3.49) (Zhang 2017, PMID 29100446) Shared tobacco exposure and inflammation complicate causality
Familial susceptibility GWAS of 685 familial cases plus replication/meta-analysis in 1,993 familial cases and 33,690 controls identified susceptibility variants (Byun 2018, PMID 29924316) Familial aggregation is polygenic; variants are not screening tests
Family history and EGFR Meta-analysis examined inherited/familial correlates of somatic EGFR status but found heterogeneous evidence (Cheng 2019, PMID 31703574) Family history does not substitute for tumor testing
Radon/occupational/indoor combustion Consistently catalogued risk domains in never-smoker reviews (Pallis 2013, PMID 23921082; Rivera 2016, PMID 26667338) Exposure-specific adenocarcinoma effect sizes vary and are not pooled here
Urban-rural access and exposure US rural areas had higher lung-cancer incidence and mortality; racial and sex patterns differed over 2001–2021 (Howlader 2025, PMID 40682793) All lung cancer; geography combines exposure, screening, treatment, and deprivation

The foundational TCGA analysis of 230 resected adenocarcinomas found a mean 8.9 somatic mutations/Mb and extensive RTK–RAS–RAF pathway alteration, but a surgical genomic cohort is not an epidemiologic sample and under-represents advanced and never-smoker disease (Cancer Genome Atlas 2014, PMID 25079552). Genomic frequency tables should therefore name population, stage, assay, and smoking distribution rather than present a single universal percentage.

How to read conflicting estimates

Five denominators are commonly conflated in this literature:

Denominator What it can answer What it cannot answer
All incident lung cancers Histology share and population burden Driver prevalence among tested adenocarcinomas
Histologically confirmed adenocarcinoma Subtype-specific incidence and survival Burden among unbiopsied or unspecified cases
Resected adenocarcinoma Early-stage pathology and genomics Metastatic-disease driver distribution (Cancer Genome Atlas 2014, PMID 25079552)
Advanced adenocarcinoma submitted for testing Treatment-relevant driver yield Population incidence; testing selection can be large (Shi 2014, PMID 24419411)
Never-smoker adenocarcinoma Non-tobacco mechanisms and enriched drivers The causal fraction attributable to any one exposure (Díaz-Gay 2025, PMID 40604281)

Smoking status is also measured inconsistently. “Never-smoker” usually means fewer than 100 lifetime cigarettes, whereas some screening cohorts include very light former smokers; passive exposure may be self-reported by household or workplace, and biochemical assays capture only a short exposure window (Ellard 1995, PMID 7669596; Chang 2024, PMID 38042167). These definitions should travel with every estimate.

Histology assignment changed over the same decades in which incidence changed. More complete immunohistochemistry, smaller biopsies, and reclassification of formerly unspecified NSCLC can increase the recorded adenocarcinoma fraction without changing underlying biology. The international time-trend reconstruction explicitly modelled missing histology, while the Japanese analysis used multiple imputation for missing stage and histology; their estimates are therefore method-dependent rather than direct counts alone (Nguyen 2022, PMID 35138642; Luo 2025, PMID 39914442).

Survival comparisons require equal caution. Better survival among never-smokers may reflect younger age, lower competing mortality, driver-positive treatment, stage distribution, and access to testing; observational adjustment cannot remove all of these differences (Clément-Duchêne 2016, PMID 26730864). Similarly, urban-rural mortality gaps cannot be labelled exposure effects because stage, screening, comorbidity, treatment access, and socioeconomic deprivation sit on the same pathway (Howlader 2025, PMID 40682793).

Prevention and equity implications

Tobacco control remains the highest-yield population intervention: modelling across 1975–2020 attributes the largest share of averted US lung-cancer deaths to prevention, while screening and treatment contribute additional gains (Goddard 2025, PMID 39636625). Yet tobacco-only framing creates two blind spots: exposure reduction must also address second-hand smoke and ambient pollution, and diagnostic systems must recognize lung cancer in people who never smoked (Hackshaw 1997, PMID 9365295; Hamra 2014, PMID 24911630).

The Taiwan TALENT cohort enrolled never-smokers or very light former smokers aged 55–75 with additional risk factors. It demonstrated feasibility and substantial detection, especially among participants with family history, but without randomization it cannot quantify mortality reduction or separate useful early detection from overdiagnosis (Chang 2024, PMID 38042167). Exporting its criteria to lower-incidence settings would change positive predictive value and downstream-harm balance.

Open questions

Measurement priorities

Future studies should report histology, smoking definition, ancestry, sex, exposure window, stage, assay, and calendar period together. Without those denominators, apparent geographic or sex differences can reflect case mix, diagnostic practice, or screening rather than biology.

  • Can a never-smoker risk model combining family history, ancestry, air pollution, lung disease, and germline variation identify a group with favourable CT benefit-to-harm balance? TALENT establishes yield but not mortality benefit (Chang 2024, PMID 38042167).
  • How much of the modern rise in localized adenocarcinoma is true incidence versus CT-driven detection and classification change (Nguyen 2022, PMID 35138642; Luo 2025, PMID 39914442)?
  • Does reducing PM2.5 exposure lower EGFR-mutant adenocarcinoma incidence on a measurable time scale, as the inflammatory promoter model predicts (Hill 2023, PMID 37020004)?
  • Which geographically varying mutational signatures in never-smokers can be assigned to modifiable exposures rather than endogenous processes (Díaz-Gay 2025, PMID 40604281)?
  • How should population-mortality gains be decomposed among tobacco control, screening, and molecular treatment without double-counting interacting effects (Howlader 2020, PMID 32786189; Goddard 2025, PMID 39636625)?

References

  1. Barta JA, et al. Global Epidemiology of Lung Cancer. Ann Glob Health. 2019. PMID 30741509
  2. Luo G, et al. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med. 2025. PMID 39914442
  3. Nguyen PT, et al. Trends in lung cancer incidence by gender, histological type and stage at diagnosis in Japan, 1993 to 2015: A multiple imputation approach. Int J Cancer. 2022. PMID 35138642
  4. Boffetta P, et al. Involuntary smoking and lung cancer. Scand J Work Environ Health. 2002. PMID 12058801
  5. Hackshaw AK, et al. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ. 1997. PMID 9365295
  6. Kurahashi N, et al. Passive smoking and lung cancer in Japanese non-smoking women: a prospective study. Int J Cancer. 2008. PMID 17935128
  7. Ellard GA, et al. Urinary nicotine metabolite excretion and lung cancer risk in a female cohort. Br J Cancer. 1995. PMID 7669596
  8. Chang GC, et al. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study. Lancet Respir Med. 2024. PMID 38042167
  9. Hill W, et al. Lung adenocarcinoma promotion by air pollutants. Nature. 2023. PMID 37020004
  10. Díaz-Gay M, et al. The mutagenic forces shaping the genomes of lung cancer in never smokers. Nature. 2025. PMID 40604281
  11. Shi Y, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014. PMID 24419411
  12. Rivera GA, et al. Lung Cancer in Never Smokers. Adv Exp Med Biol. 2016. PMID 26667338
  13. Hamra GB, et al. Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis. Environ Health Perspect. 2014. PMID 24911630
  14. Pallis AG, et al. Lung cancer in never smokers: disease characteristics and risk factors. Crit Rev Oncol Hematol. 2013. PMID 23921082
  15. Li T, et al. Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014. Clin Lung Cancer. 2021. PMID 33414054
  16. Clément-Duchêne C, et al. Survival among Never-Smokers with Lung Cancer in the Cancer Care Outcomes Research and Surveillance Study. Ann Am Thorac Soc. 2016. PMID 26730864
  17. Zhang X, et al. Chronic obstructive pulmonary disease and risk of lung cancer: a meta-analysis of prospective cohort studies. Oncotarget. 2017. PMID 29100446
  18. Byun J, et al. Genome-wide association study of familial lung cancer. Carcinogenesis. 2018. PMID 29924316
  19. Cheng YI, et al. Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review. BMC Cancer. 2019. PMID 31703574
  20. Howlader N, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020. PMID 32786189
  21. Goddard KAB, et al. Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. JAMA Oncol. 2025. PMID 39636625
  22. Howlader N, et al. Urban-rural disparities in lung cancer incidence and mortality patterns in Black and White populations. Cancer. 2025. PMID 40682793
  23. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024. PMID 38572751
  24. Cancer Genome Atlas Research Network, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014. PMID 25079552
  25. Mohan A, et al. Increasing incidence of adenocarcinoma lung in India: Following the global trend? Indian J Cancer. 2016. PMID 27146752